A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether six months of daily finasteride (PROSCAR),
following an initial negative prostate biopsy, will improve the detection of prostate cancer
on repeat biopsy.
144 subjects with an initial negative prostate biopsy will be randomized to receive either
finasteride or placebo for 6 months. The subjects will undergo a second prostate biopsy
following drug intervention. PSA (prostate specific antigen) measurements, testosterone
levels, and quality of life questionnaires will also be assessed during the study. The two
groups will then be compared.